Editors
- Matthias Preusser, Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria
- Michael Weller, Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
Series editor: Michele Ghielmini, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
Contributors
Chapter 1 - Epidemiology, Pathogenesis and Risk Factors of Brain Tumours
- L Bauchet - Department of Neurosurgery and French Brain Tumor DataBase, Hôpital Gui de Chauliac, Montpellier, France
- V Rigau - Department of Pathology and French Brain Tumor DataBase, Hôpital Gui de Chauliac, Montpellier, France
Chapter 2 - Clinical Presentation, Differential Diagnosis and Response Assessment of Gliomas
- R Henriksson - Regional Cancer Centre Stockholm Gotland; Department of Radiation Sciences, Umeå University Hospital, Umeå, Sweden
- M Bergqvist - Department of Oncology, Gävle Hospital, Gävle, Sweden; Department of Radiation Sciences & Oncology, Umeå University Hospital, Umeå, Sweden
Chapter 3 - Histology and Molecular Pathology of Gliomas
- P Wesseling - Department of Pathology, VU University Medical Center/Brain Tumor Center, Amsterdam, Netherlands; Diagnostic Laboratory, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pathology, University Medical Center Utrecht, Netherlands
Chapter 4 - Treatment Strategies for Anaplastic Astrocytoma and Glioblastoma
- M Weller - Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland
- M Hegi - Laboratory of Brain Tumor Biology and Genetics, Service of Neurosurgery, Department of Clinical Neurosciences, University Hospital Lausanne, Lausanne, Switzerland
Chapter 5 - Treatment Strategies for Low-grade Gliomas
- BG Baumert - Department of Radiation-Oncology, MediClin Robert-Janker-Clinic; Clinical Cooperation Unit Neurooncology, University of Bonn Medical Centre, Bonn, Germany and Department of Radiation-Oncology, Paracelsus Clinic Osnabrueck, Germany
- AF Hottinger - Departments of Clinical Neurosciences & Oncology, CHUV Lausanne University Hospital, Lausanne University, Lausanne, Switzerland
Chapter 6 - The Essentials in Radiation Oncology for Brain Tumours
- M Brada - Academic Unit of Radiation, Oncology Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK
- T Ajithkumar - Department of Clinical Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
Chapter 7 - Surgery, Indications and Limitations
- O Schnell - Department of Neurosurgery, Klinikum der Ludwig-Maximilians-Universität München Campus Grosshadern, Munich, Germany; Department of Neurosurgery, Medical Center - University of Freiburg, Freiburg, Germany
- J-C Tonn - Department of Neurosurgery, Klinikum der Ludwig-Maximilians-Universität München Campus Grosshadern, Munich, Germany
Chapter 8 - Management of CNS Metastases
- M Preusser - Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria
Chapter 9 - Treatment of Oligodendroglioma (IDHmt, 1p/19q Codeleted)
- F Ducray - Neuro-Oncology, Hôpital Neurologique de Lyon, Lyon, France
- MJ van den Bent - Department of Neuro-Oncology/Neurology, Erasmus MC Cancer Center, Rotterdam, Netherlands
Chapter 10 - Classification and Treatment Strategies of Meningiomas
- C Mawrin - Department of Neuropathology, Otto-von-Guericke-University, Magdeburg, Germany
- M Preusser - Department of Medicine I, Comprehensive Cancer Center Vienna, Vienna, Austria
Chapter 11 - Classification and Treatment of Paediatric Brain Tumours
- R Riccardi - Università Cattolica del Sacro Cuore, Rome, Italy
- D Rizzo - Università Cattolica del Sacro Cuore, Rome, Italy
- F Giangaspero - Department of Radiological, Oncological and Anatomopathological Sciences, University Sapienza of Rome, Rome, Italy; IRCCS Neuromed, Pozzilli, Italy
Chapter 12 - Anticoagulation and Management of Seizures and Brain Oedema in Brain Tumour Patients
- C Marosi - Medical University of Vienna, Clinical Division of Medical Oncology, Department for Internal Medicine I, Vienna, Austria
- S Oberndorfer - Department for Neurology, University Clinic St. Pölten, KLPU, KLI-Clinical Neurology and Neuropsychology, St. Pölten, Austria
Chapter 13 - Management of Spinal Tumours
- S-O Eicker - Department of Neurosurgery, University Medical Center, Hamburg-Eppendorf, Germany
- M Westphal - Department of Neurosurgery, University Medical Center, Hamburg-Eppendorf, Germany
Declarations of interest
- T Ajithkumar: No conflicts of interest.
- L Bauchet: No conflicts of interest.
- BG Baumert: Travel support from MSD, Roche, Noxxon; compensation for advisory board participation from Noxxon.
- M Bergqvist: Advisory board for Lilly Pharma, MSD, Bristol-Myers-Squibb.
- M Brada: No conflicts of interest.
- F Ducray: Research support from Roche, GlaxoSmithKline, Bristol-Myers-Squibb, UCB, Novocure.
- S-O Eicker: Scientific advisor for Stryker, Spineart.
- F Giangaspero: No conflicts of interest.
- M Hegi: Compensation for lectures or advisory board participation from MSD, Roche/Genentech, MDxHealth, Novocure.
- R Henriksson: No conflicts of interest.
- AF Hottinger: Travel support from Roche, MSD, Novocure.
- C Marosi: No conflicts of interest.
- C Mawrin: No conflicts of interest.
- S Oberndorfer: No conflicts of interest.
- M Preusser:Research support from Böhringer- Ingelheim, GlaxoSmithKline, Merck Sharp & Dome, Roche; honoraria for lectures, consultation or advisory board participation from Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, AstraZeneca.
- R Riccardi: No conflicts of interest.
- V Rigau: No conflicts of interest.
- D Rizzo: No conflicts of interest.
- O Schnell: Honoraria for advisory board participation or consulting from Novocure, Roche.
- J-C Tonn: No conflicts of interest.
- MJ van den Bent: Research support from Roche, Abbvie; honoraria from Roche, Abbvie, Novocure, Actelion, Merck Ag, Cavion.
- M Weller: Research grants from Acceleron, Actelion, Alpinia Institute, Bayer, Isarna, MSD, Merck & Co, Novocure, PIQUR, Roche; honoraria for lectures or advisory board participation or consulting from Celldex, Immunocellular Therapeutics, Isarna, Magforce, MSD, Merck & Co, Northwest Biotherapeutics, Novocure, Pfizer, Roche, Teva.
- P Wesseling: No conflicts of interest.
- M Westphal: No conflicts of interest.
